CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

ABSTRACT:

Background & aims

The CpG island methylator phenotype (CIMP), defined by a high frequency of aberrantly methylated genes, is a characteristic of a subclass of colon tumors with distinct clinical and molecular features. Cohort studies have produced conflicting results on responses of CIMP-positive tumors to chemotherapy. We assessed the association between tumor CIMP status and survival of patients receiving adjuvant fluorouracil and leucovorin alone or with irinotecan (IFL).

Methods

We analyzed data from patients with stage III colon adenocarcinoma randomly assigned to groups given fluorouracil and leucovorin or IFL after surgery, from April 1999 through April 2001. The primary end point of the trial was overall survival and the secondary end point was disease-free survival.

SUBMITTER: Shiovitz S 

PROVIDER: S-EPMC4143495 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature